@article {10.3844/ajbbsp.2020.235.243,
article_type = {journal},
title = {MicroRNA-92a: The Administrator of Certain Diseases},
author = {Sun, Zhiyuan and Xu, Qing and Tian, Xiaoyi and Yang, Yingjie and Wang, Qinglu and Tian, Xuewen},
volume = {16},
number = {2},
year = {2020},
month = {May},
pages = {235-243},
doi = {10.3844/ajbbsp.2020.235.243},
url = {https://thescipub.com/abstract/ajbbsp.2020.235.243},
abstract = {MicroRNA-92a (miR-92a) is an evolutionarily conserved noncoding small RNA that can regulate gene expression after transcription. Previous studies have found that miR-92a is overexpressed in many tumors and can regulate numerous tumor suppressor genes negatively, with relevant effects on the development of different tumors, by regulating the DUSP10/c-Jun N-terminal kinase (JNK), phosphatase and tensin homologs (PTEN)/AKT, Wnt and EP4/Notch1 signaling axes. MiR-92a also promotes the proliferation and migration of vascular smooth muscle cells (VSMCs) through the Rho-associated coiled-coil-forming kinase/myosin light chain kinase signaling pathway and inhibits VSMC apoptosis through the MKK4/JNK signaling pathway. Moreover, miR-92a affects endothelial functions; mediates endothelial dysfunction in chronic kidney diseases; mediates THBS1 inhibition; promotes the migration, proliferation and angiogenesis of neighboring endothelial cells (ECs); mediates the Nrf2/KEAP1/ARE signaling pathway to regulate vascular endothelial aging; and is involved in immune responses to activate ECs. This review summarizes the potential role and pathogenic mechanism of the miR-92a gene in certain diseases to provide possible new treatment options.},
journal = {American Journal of Biochemistry and Biotechnology},
publisher = {Science Publications}
}